	US 11,879,016 B2
	Chimeric antigen receptor
Martin Pulé, London (GB); John Anderson, London (GB); and Simon Thomas, London (GB)
Assigned to AUTOLUS LIMITED, London (GB)
Filed by AUTOLUS LIMITED, London (GB)
Filed on Mar. 9, 2021, as Appl. No. 17/196,670.
Application 17/196,670 is a continuation of application No. 15/123,331, granted, now 10,975,162, previously published as PCT/GB2015/050649, filed on Mar. 6, 2015.
Claims priority of application No. 1403972 (GB), filed on Mar. 6, 2014.
Prior Publication US 2021/0403596 A1, Dec. 30, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/30 (2006.01); C07K 14/725 (2006.01); C07K 14/705 (2006.01); A61K 35/17 (2015.01); A61K 38/17 (2006.01); A61K 39/395 (2006.01); C12N 15/85 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/3084 (2013.01) [A61K 35/17 (2013.01); A61K 38/179 (2013.01); A61K 38/1774 (2013.01); A61K 39/39558 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C12N 15/85 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/52 (2013.01); C07K 2317/53 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2319/00 (2013.01); C07K 2319/03 (2013.01); C07K 2319/20 (2013.01); C07K 2319/30 (2013.01); C12N 2510/00 (2013.01)]

2 Claims

1. A method for treating cancer which comprises the step of administering a T cell to a subject,

wherein the T cell expresses a chimeric antigen receptor (CAR) comprising

a) a disialoganglioside (GD2)-binding domain and spacer, shown as amino acids 21 to 311 of SEQ ID NO: 29,

b) a hydrophobic alpha helical transmembrane domain, and

c) a CD28-CD3Zeta endodomain shown as SEQ ID NO: 17; and

wherein the cancer is a melanoma, medulloblastoma, soft-tissue sarcoma, osteosarcoma or small-cell lung cancer.